Endstage Renal Disease Clinical Trial
Official title:
Improving Adherence in Renal Dialysis Patients; a Randomized Crossover Trial for an Electronic Intervention
Dialysis treatment non-adherence is a prevalent problem among the end-stage renal population
receiving chronic hemodialysis. The complications associated with missed or shortened
dialysis sessions are serious and frequently require emergent medical care or
hospitalization. Previous studies have shown that electronic messages have significantly
improved attendance rates in a primary care setting, but these messages have not been
validated in the chronic dialysis population.
An electronic intervention has been developed by Epharmix, a WUSTL IDEA Labs
(ideas.wustl.edu) team, which has the capacity to use automated SMS text messages and/or
phone calls to notify patients prior to each upcoming appointment, as well as alert a
designated patient advocate. Patients receiving the messages are provided with key contact
information for a dialysis rescheduling phone line, transportation resources, social work
services, etc. They may also receive instructions on what to do if they are experiencing
physical symptoms and need educational facts about dialysis. In particular, the intervention
is designed to demonstrate to patients that the center cares and is concerned for their
health and wellbeing. This intervention may potentially improve patient adherence to their
scheduled sessions, increase patient satisfaction with their treatment, and prevent medical
complications associated with missed dialysis appointments.
This study aims to determine whether an electronic intervention, which sends SMS text
messages or phone calls of key dialysis treatment information, is able to improve dialysis
treatment session attendance among dialysis patients with a history of poor attendance. We
secondarily aim to identify the factors that may be barriers to dialysis treatment session
attendance and the emergency department or hospital utilization associated with missed
dialysis treatments.
Patients will be prospectively identified, recruited, and randomized into two groups. Group A
will receive the electronic intervention prior to their appointments; Group B will not
receive any electronic intervention. After 8 weeks, crossover will occur for both groups and
the study will continue for an additional 8 weeks. Participants' clinic records will be
reviewed to determine the numbers of missed and attended appointments, as well as records of
ED visits and hospital admissions. Subjects will be asked to complete a post-study
satisfaction questionnaire.
Dialysis treatment non-adherence is a prevalent problem among the end-stage renal population
receiving chronic hemodialysis. The complications associated with missed or shortened
dialysis sessions are serious and frequently require emergent medical care or
hospitalization. Previous studies have shown that electronic messages have significantly
improved attendance rates in a primary care setting, but have not been validated in the
chronic dialysis population.
An electronic intervention has been developed by Epharmix, a WUSTL IDEA Labs
(ideas.wustl.edu) team, which has the capacity to use SMS text messaging to phone call
recordings to notify patients prior to each of their upcoming appointment times, with the
option of also alerting a designated patient advocate. Patients receiving the messages are
provided with key contact information for a dialysis rescheduling phone line, transportation
resources, social work services, etc. This intervention may potentially improve patient
adherence with scheduled sessions, increase patient satisfaction with their treatment and
prevent medical complications associated with missing dialysis.
This study aims to determine whether an electronic intervention, which sends SMS text
messages or phone calls of key dialysis treatment information, is able to improve dialysis
session attendance among patients with a history of poor attendance. Our secondary aim is to
identify factors that may be barriers to dialysis appointment attendance and are associated
with emergency department (ED) or hospital utilization.
Procedures: Dialysis patients of the Chromalloy American Kidney Center (CAKC) at Barnes
Jewish Hospital (BJH) and the Washington University Dialysis Center (WUDC) will be included
in this study. Two cohorts will be prospectively identified, one group consisting of
individuals with a history of occasional non-attendance to treatment sessions, defined as 2-3
missed sessions out of 24 consecutive sessions in the past 8 weeks; the other group
consisting of individuals who are frequently non-adherent (4-6 missed sessions in the past 24
consecutive sessions). Patients from each cohort will be recruited and then randomized to
either the experimental or the control group. Group A will receive the electronic
intervention featuring automated SMS text message and/or phone call prior to their
appointments; Group B will not receive any electronic intervention. After 8 weeks, crossover
will occur for both groups and the study will continue for an additional 8 weeks.
At time of enrollment, all subjects will be asked to complete a questionnaire to determine
the demographic characteristics of the study population of interest and identify possible
socio-economic factors contributing to non-adherence to the prescribed 3 times weekly
dialysis schedule. The participants' clinic records will be reviewed to determine the numbers
of missed and attended appointments, as well as records of ED visits and hospital admissions
through BJH. Subjects will be asked to complete a post-questionnaire to rate their
satisfaction with their current schedule of dialysis and their satisfaction with the
electronic intervention.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03023748 -
Intravenous Paricalcitol in Chronic Hemodialysis Patients
|
Phase 4 | |
Terminated |
NCT00776191 -
Randomized Multicenter Cross-over Study to Compare the Effect of Physioneal 35 to 40 on the Protein Metabolism
|
Phase 4 | |
Completed |
NCT00745914 -
Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) Agonist in Diabetic End-Stage Renal Disease Patients
|
N/A | |
Completed |
NCT02981706 -
Comparison of AVF Versus AVG in Elderly Patients Starting Dialysis
|
N/A | |
Completed |
NCT02946229 -
Data Collection for Next Generation Ultrasound Technology Development
|
N/A | |
Completed |
NCT02976246 -
Effect of Vitamin K2 (MK7) on Cardiovascular and Bone Disease in Dialysis Patients
|
Phase 4 | |
Completed |
NCT02966028 -
Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)
|
Phase 2 | |
Recruiting |
NCT02957877 -
LMWH Infusion as Anticoagulation for Home HD
|
Phase 4 | |
Completed |
NCT00745719 -
Parathyroidectomy in Endstage Renal Disease
|
N/A | |
Completed |
NCT03010072 -
The Effect of Phosphate Lowering Using Sucroferric Oxyhydroxide (PA21) on Calcification Propensity of Serum
|
Phase 2 | |
Recruiting |
NCT03020303 -
Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease
|
Phase 3 | |
Completed |
NCT00745589 -
Sevelamer Hydrochloride in Peritoneal Dialysis Patients
|
N/A | |
Not yet recruiting |
NCT02976688 -
Effects of Short-chain Fatty Acids on Inflammatory and Metabolic Parameters in Maintenance Hemodialysis
|
Phase 2/Phase 3 | |
Withdrawn |
NCT00502268 -
Vitamin D and Carboxy PTH Fragments in Coronary Calcification
|
Phase 4 | |
Completed |
NCT02207153 -
Risk Assessment by Cardiovascular Biomarkers in Chronic Dialysis Patients
|
||
Completed |
NCT02977117 -
The Effect of Increasing Dialysate Magnesium on Calcification Propensity in Subjects on Haemodialysis
|
Phase 2 | |
Completed |
NCT02866214 -
Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients.
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT03054454 -
A Podiatry Led MDT Intervention to Reduce the Burden of Foot Disease in Patients With End Stage Kidney Failure
|
N/A |